Prof. dr. W.J.M. Mulder

Main activities
Research, Teaching
Focus of research

I established the Nanomedicine Laboratory at Mount Sinai in New York (Nano-TMII):
At Nano-TMII we develop nanomedical approaches towards molecular imaging and targeted therapy of cancer and cardiovascular disease in a preclinical setting. To that aim my lab developed libraries of nanoparticle probes based on the lipoprotein architecture to target plaque macrophages and diagnose atherosclerosis with CT, MRI and optical techniques. We also developed probes that allow apoptosis or collagen imaging of the diseased vessel wall. In parallel my lab developed complex multifunctional nanoparticles of which the size, composition and payload of drugs and diagnostic agents can be judiciously controlled. We have shown their effectiveness for targeted imaging and therapy in mouse models of cancer. I also established a research line aimed at targeted nanotherapy of atherosclerotic disease. We explored this new atherosclerosis treatment paradigm in rabbit and mouse models of atherosclerosis and show its ability to induce a rapid reduction of plaque inflammation. These studies served as the foundation of clinical trials we have initiated in September 2011 at the AMC Amsterdam where I hold a position as of January 2012. In December 2011 we contributed a seminal review paper to Nature Reviews Drug Discovery with the title “Perspectives and opportunities for nanomedicine in the management of atherosclerosis”. The goal of my research activities is to further develop state-of-the-art nanomedical approaches, develop imaging readouts and test them preclinically at Sinai, while complementary translational studies and clinical trials will be done at the AMC.

Key publications
  • Tang J, Baxter S, Menon A, Alaarg A, Sanchez-Gaytan BL, Fay F, Zhao Y, Ouimet M, Braza MS, Longo VA, Abdel-Atti D, Duivenvoorden R, Calcagno C, Storm G, Tsimikas S, Moore KJ, Swirski FK, Nahrendorf M, Fisher EA, Pérez-Medina C, Fayad ZA, Reiner T, Mulder WJM, Immune cell screening of a nanoparticle library improves atherosclerosis therapy. P NATL ACAD SCI USA 2016;113 (44):E6731-E6740 [PubMed]
  • Zhao Y, Fay F, Hak S, Manuel Perez-Aguilar J, Sanchez-Gaytan BL, Goode B, Duivenvoorden R, de Lange Davies C, Bjørkøy A, Weinstein H, Fayad ZA, Pérez-Medina C, Mulder WJM, Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy. NAT COMMUN 2016;7:11221 [PubMed]
  • Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, Otten MJ, Zaidi N, Lobatto ME, van Rijs SM, Priem B, Kuan EL, Martel C, Hewing B, Sager H, Nahrendorf M, Randolph GJ, Stroes ESG, Fuster V, Fisher EA, Fayad ZA, Mulder WJM, A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. NAT COMMUN 2014;5:3065 [PubMed]
  • Mulder WJM, Jaffer FA, Fayad ZA, Nahrendorf M, Imaging and nanomedicine in inflammatory atherosclerosis. SCI TRANSL MED 2014;6 (239):239sr1 [PubMed]
  • Lobatto ME, Fuster V, Fayad ZA, Mulder WJM, Perspectives and opportunities for nanomedicine in the management of atherosclerosis. NAT REV DRUG DISCOV 2011;10 (11):835-852 [PubMed]
All Publications
Research programmes

Cardiovascular Nanomedicine and Molecular Imaging

Prof. dr. W.J.M. Mulder

PhD Students
M.M.T. van Leent
B. Priem
M.L. Senders

Other research related activities
  • Associate Professor of Radiology, Mount Sinai School of Medicine
Current research funding
  • AMC (Vrijgesteld)
  • Sensi Pharma B.V.
  • Toegepaste en Technische Wetenschappen (TTW)
  • ZonMw